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Currently, there is no licensed Shigella vaccine; however, various promising live-attenuated
vaccine candidates have emerged, including CVD1208S (∆guaBA, ∆set, ∆sen S. flexneri
2a), which was shown to be safe and immunogenic in Phase 1 clinical trials. Here, we report
the immune responses elicited in an outpatient Phase 2 clinical trial in which subjects were
vaccinated with CVD 1208S. Oral immunization with CVD 1208S elicited high anti-S. flexneri
2a LPS and IpaB antibody responses as well as an acute plasmablast (PB) infiltration in
peripheral blood 7 days after immunization. PB sorted based on their expression of hom-
ing molecules confirmed that cells expressing integrin α4β7 alone or in combination with
CD62L were responsible for antibody production (as measured by ELISpot). Furthermore,
using high-color flow-cytometry, on day 7 after immunization, we observed the appear-
ance of conventional PB (CPB, CD19dim CD20− CD27+high CD38+high CD3−), as well as
a PB population that did not express CD27 (CD27− PB; pre-plasmablasts). The pattern of
individual or simultaneous expression of homing markers (integrin α4β7, CD62L, CXCR3,
and CXCR4) suggested that CPB cells homed preferentially to the inflamed gut mucosa. In
contrast, ~50% CD27− PB cells appear to home to yet to be identified peripheral lymphoid
organs or were in a transition state preceding integrin α4β7 upregulation. In sum, these
observations demonstrate that strong immune responses, including distinct PB subsets
with the potential to home to the gut and other secondary lymphoid organs, can be elicited
after a short time of exposure to a shigella oral vaccine.
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INTRODUCTION
The intestine constitutes the largest immunological organ in the
body and is home to the majority of lymphocytes (1, 2). In this
organ, pathogens such as Shigella and Salmonella activate antigen
presenting cells (APC) [e.g., dendritic cells (DC)] that migrate
to mesenteric lymph nodes (MLN) where they stimulate lym-
phocytes (3). Subsequently, activated lymphocytes migrate to the
intestinal lamina propria, as effector immune cells, largely via
blood (2, 4–6). Lymphocytes homing to the intestine express both
CCR9, a chemokine receptor mediating homing to the small intes-
tine (1, 2, 4, 7, 8) and integrin α4β7 (9), a gut-specific homing
receptor that recognizes Mad-CAM1 on the endothelial venules of
the intestine. On the other hand, lymphocytes expressing CD62L
(L-selectin) home preferentially to peripheral lymph nodes by
binding to Gly-CAM1, which is found on high endothelial venules
through which lymphocytes enter secondary lymphoid organs
(10–12). Expression of these homing markers on lymphocytes is
regulated by intestinal DC during antigen presentation (3–6).
Efforts are ongoing to better characterize the intestinally
derived immune responses to Shigella infection. This information
will be invaluable to guide the development of novel live oral vac-
cines against a pathogen whose global burden is well-documented
(13, 14). After Shigella enters the host it infiltrates the gut epithe-
lium, primarily via M cells (15–17). Innate immunity is often
insufficient to clear a Shigella infection, particularly once it enters
epithelial cells where this microorganism can move freely inside
and between cells (18). As the infection progresses, Shigella acti-
vates the adaptive immune system and induces humoral (anti-
body) and effector T cell (CMI) responses, as well as memory (B
and T) responses (15, 17–24). Various lines of evidence point to
the importance of the B cell compartment in protection against
repeated Shigella infections. For one, serotype-specific protection
has been demonstrated in field (25–27) and clinical settings (28,
29) in humans and in primate studies (30). Serotype-specific IgA
and IgG antibodies as well as circulating IgA antibody-secreting
cells (ASC) directed against the (LPS) O-antigen have been cor-
related with protection (21, 23, 29–37). More recent evidence
suggests that antibodies to invasion plasmid antigens (Ipa) also
play an important role in protection (23, 24, 38–42). Among B
cells, plasmablasts (PB) and plasma cells (PC) are responsible for
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antibody production/secretion. PB, which are not yet fully dif-
ferentiated PC, proliferate extensively (43) and actively secrete
antibodies while migrating to the target tissues where they will
differentiate and home as PC. PB numbers peak in peripheral
blood at day 6 or 7 following immunization or infection by Shigella
(44) and other pathogens (43, 45–53). This transient peak of PB in
peripheral blood, which coincides with the acute phase of immune
responses, has been termed “acute PB infiltration” and used to
differentiate from steady-state PB (54, 55). This “acute PB infiltra-
tion” has also been described in secondary infection/vaccination
responses around the same time frame (7–9 days). While in a
primary infection/vaccination, the “acute PB infiltration” is evi-
dence of lymphocyte priming; in secondary infection/vaccination,
it most likely indicates activation of memory B cells (BM). PB
recently activated in the intestine, either by oral vaccination (19, 20,
56–59) or intestinal infections (60–62) are identified in circulation
as ASC expressing integrin α4β7 (62, 63), implying a preferential
homing of these cells to the intestinal lamina propria. Other hom-
ing markers, such as CXCR3 and CXCR4, which promote homing
to inflamed tissues and bone marrow, respectively, have also been
reported in PB cells (64).
Designing novel oral live-attenuated Shigella vaccine candi-
date strains requires striking an optimal balance between limited
reactogenicity and induction of protective, long-lasting immunity.
Due to the difficulty in achieving this fine balance, the goal of gen-
erating effective oral live-attenuated vaccine strains against Shigella
has proven difficult, and occasionally resulted in vaccine-related
reactogenicity. No licensed vaccines against Shigella are currently
available (23, 24); however, various promising live-attenuated oral
vaccine candidates have been developed. CVD 1208 and CVD
1208S, developed at the Center for Vaccine Development (CVD) of
the University of Maryland, were constructed by introducing pre-
cise deletions in the wild-type S. flexneri 2a strain 2457T (65). Both
vaccine strains are impaired in their ability to synthesize guanine
nucleotides (∆guaBA), and lack Shigella enterotoxins (ShET) 1
and 2, encoded by set and sen, respectively. After CVD 1208 showed
promising results in clinical trials (66), it was reconstructed using
animal-free media to comply with regulatory requirements for use
in humans, and shown to be well-tolerated and immunogenic in
Phase 1 clinical trials (65). Herein, we report the results of a Phase
2 clinical trial in which a new lot of CVD 1208S grown in an animal
product-free medium different from the one used previously. After
the first vaccine dose, some subjects experienced fever and/or diar-
rhea, which was attributed to the new soy-based medium used to
grow CVD 1208S. This prompted the initiation of antibiotic treat-
ment 1–4 days post-immunization. Here, we describe the humoral
immune responses and the homing patterns of PB cells elicited in
these volunteers, as well as a PB population that lacks CD27 expres-
sion (CD27− PB) and appears to migrate to lymphoid organs
different from “conventional” PB (CPB) cells.
MATERIALS AND METHODS
SUBJECTS AND STUDY DESIGN
Healthy male and non-pregnant female volunteers aged 18–
49 years were recruited from the Baltimore/Washington, DC area
for this randomized, placebo-controlled, and double-masked clin-
ical trial (Table 1). Volunteers were required to be in good health




Ageb 37.2 32.3 36.5
(95% CIc) (33.2–41.1) (12.1–52.6) (32.8–40.1)
Weightd 182 222 188
(95% CI) (165–200) (24–421) (168–208)
BMIe 28 32 28
(95% CI) (25–31) (1–62) (25–32)
Femalef 35 0 30
(95% CI) (13–58) (0–0) (10–50)
Blackf 82 67 80
(95% CI) (64–100) (13–100) (62–98)
Asianf 0 33 5
(95% CI) (0–0) (0–87) (0–15)
Whitef 18 0 15







as evidenced by medical history, physical examination, and labora-
tory evaluation, as previously described (65, 66). Serial cohorts of
volunteers who satisfied eligibility criteria and provided informed,
written consent were randomly allocated 5:1 to receive vaccine
(n= 50) or placebo (n= 10). Each subject was scheduled to ingest
a dose of vaccine or placebo on days 0, 28, and 56. An indepen-
dent safety monitor was charged with reviewing safety data after
each dose to recommend whether additional dosing was accept-
able. This study was approved by the Institutional Review Board
and registered on ClinicalTrials.gov (identifier NCT00866476). In
this report, we include the results of two cohorts (20 volunteers)
who received a single dose of CVD 1208S (n= 17) or placebo
(n= 3).
Halting rules
Antibiotic treatment (ciprofloxacin 500 mg by mouth twice daily
for 5 days) was not to be routinely administered to subjects unless
specific reactogenicity events occurred and were considered to be
vaccine-related: (1) one or more subjects experienced a serious
adverse reaction, or (2) two or more subjects experienced any of
the following adverse reactions: (a) fever>39°C; (b) passage of>5
diarrheal stools per day or requiring >2 L of intravenous hydra-
tion); or (c) passage of moderate dysentery (>2 dysenteric stools
per day). If these events occurred, under advisement of the Safety
Monitoring Committee, further doses of vaccine would not be
administered.
CVD1208S VACCINE CONSTRUCTION AND PREPARATION
CVD 1208S (∆guaBA, ∆sen, ∆set ) was constructed from wild-
type S. flexneri 2a strain 2457T by a series of allelic exchange

























































Toapanta et al. Shigella induces gut-homing plasmablasts
reactions using suicide plasmid deletion cassette technology as
previously described (65). The vaccine was administered as a
freshly harvested formulation. The inocula were derived from
frozen master cell banks (MCB) prepared as previously described
(65), except for the change in solid media from Hy-Soy (Kerry
BioScience, Norwich, NY, USA) to APF Athena Lennox (Athena
Enzyme Systems, Baltimore, MD, USA). In short, a frozen vial
of master seed was plated onto APF LB agar plates (Lennox)
containing Congo red dye (0.01%) (Sigma-Aldrich, St. Louis,
MO, USA) and guanine (0.005%) (Sigma-Aldrich) (no antibi-
otics). After incubation (18–24 h, 37°C), single Congo red pos-
itive colonies were confirmed to be Shigella using antiserum
(Denka Seiken, Niigata, Japan). Several colonies were suspended
in sterile saline, inoculated into guanine-supplemented APF
LB agar plates, incubated overnight (37°C) in the absence of
antibiotics and harvested into sterile phosphate buffered saline
(PBS, pH 7.4) (Sigma-Aldrich). The bacterial suspension was
diluted (sterile PBS) to have an O.D. (660 nm) correspond-
ing to the desired bacterial count per milliliter. The inocula
were used within 4 h of preparation. The geometric mean of
replicate colony counts performed before and after vaccina-
tion confirmed that the expected inoculum (1× 109 CFU per
milliliter) of vaccine had been attained. Placebo consisted of
buffer solution mixed with cornstarch USP (ScicenceLab.com
Inc., Houston, TX, USA) added to match the turbidity of the
vaccine (65).
Twenty outpatient volunteers were fasted 90 min before drink-
ing 120 ml of a solution containing 2 g of NaHCO3 in 150 ml
distilled water to buffer gastric acid. One minute later, the volun-
teers took the vaccine (at ~109 cfu) in the remaining 30 ml of buffer
or placebo (buffer alone). The volunteers were fasted an additional
90 min after vaccination. For the remainder of the day of vacci-
nation and for the next 6 days, they recorded signs and symptoms
onto a standardized diary form which were graded for severity,
including their daily oral temperature, the occurrence of consti-
tutional symptoms (headache, anorexia, malaise, and abdominal
cramps), vomiting, and the character of all stools passed as either
formed or loose (defined as stools, which take the shape of the con-
tainer) and whether they contained visible blood. They returned to
the study center on days 3 and 7 after vaccination to review diary
cards. Antibiotics were given only in the event of unacceptable
reactogenicity.
SERUM ANTIBODY RESPONSES
IgA and IgG antibody titers against LPS and recombinant Shigella
IpaB were measured in serum before vaccination as well as on days
7, 14, and 28 post-immunization by enzyme-linked immunosor-
bent assay (ELISA) as previously described (65). Titers were calcu-
lated from linear regression curves and expressed as the reciprocal
serum dilution that produced an O.D. of 0.2 above the blank, in
ELISA Units (EU) per milliliter. Seroconversion was defined as a
fourfold or higher rise in antigen-specific serum antibody post-
vaccination compared to the pre-vaccination titer. The LPS from
S. flexneri 2a LPS was purified by the hot aqueous phenol extrac-
tion method of Westphal (67) and the Shigella IpaB protein was
purified as recombinant proteins expressed in E. coli as previously
described (20, 21, 65, 68).
ANTIBODY-SECRETING CELLS
In order to evaluate intestinal priming by CVD 1208S, antigen-
specific circulating IgA and IgG ASC were measured before (day
0) and 7 days after vaccination by enzyme-linked immunospot
assay (ELISpot) as previously described (65, 66). In short, nitro-
cellulose plates (Millipore, Billerica, MA, USA) were coated with
Shigella antigens including S. flexneri 2a LPS and Shigella IpaB
(0.1 mg/ml), which were prepared according to previously pub-
lished methods (20, 21, 65, 68). Coated plates were washed (3×)
with PBS and blocked with 10% FBS RPMI (Gibco, Grand Island,
NY, USA) for 2 h (5% CO2, 37°C). Peripheral blood mononuclear
cells (PBMC) were then seeded (2.5× 105 per well) in quadru-
plicate and incubated for 14–16 h (5% CO2, 37°C). Subsequently,
plates were washed with PBS-Tween (0.05%) and HRP-labeled
goat anti-human IgA (1:2000) (Jackson ImmunoResearch Lab-
oratories, West Grove, PA, USA) as well as IgG (1:1000) (Jack-
son ImmunoResearch Laboratories) were added to the respective
plates and incubated for 1 h (37°C). Following a wash step, the
3-amino-9 ethylcarbazole C (AEC) substrate (Sigma-Aldrich) was
added and plates incubated 10–20 min in the dark. Finally, plates
were washed three times with distilled water to stop the reac-
tion. Positive ELISpot responses were defined as a post-vaccination
counts per 106 PBMC that are at least three standard deviations
(SD) above the mean pre-vaccination count for all subjects (in the
log metric); a minimum of eight cells were required, which corre-
sponds to the mean of medium negative control wells (two spots)
plus three SD (66).
CELL SORTING STRATEGY TO EVALUATE EXPRESSION OF HOMING
MOLECULES BY SHIGELLA-SPECIFIC ASC
Freshly isolated PBMC were stained with monoclonal antibod-
ies to CD19-PE-Cy7 (clone J3–119, Beckman-Coulter – BC),
CD27-PECy5 (Clone 1A4CD27, BC), CD62L-PE (Clone Dreg-56,
Becton-Dickinson – BD), and integrin α4β7 (Clone ACT-1, Mille-
nium: The Takenda Oncology Co., Cambridge, MA, USA) conju-
gated to Alexa 488 using an Alexa labeling kit (Molecular Probes).
Cells were then simultaneously sorted into four populations: B
naïve (Bn, CD19+ CD27−), (P) B memory (BM, CD19+CD27+)
expressing CD62L but not integrin α4/β7 (CD62L+ α4β7−) (M)
BM expressing integrin α4β7 but not CD62L (CD62L− α4β7+), or
(M/P) BM expressing both integrin α4β7 and CD62L (CD62L+
α4/β7+). Four-way sorting was performed in a MoFlo flow
cytometer/cell sorter system (Beckman-Coulter). Purities of the
sorted populations were 84.1–94%. The presence of Shigella-
specific IgG and IgA ASC in each sorted population was measured
as described above (see Antibody-Secreting Cells). The results are
expressed as number of spots per 1× 106 cells.
PB CELL DETERMINATIONS BY MULTICHROMATIC FLOW CYTOMETRY
Peripheral blood mononuclear cells were isolated immediately
after blood draws by density gradient centrifugation (69, 70).
Freshly isolated PBMC were re-suspended in complete media
[RMPI (Gibco, NY, USA) supplemented with 10% fetal bovine
serum (FBS) (Gemini Bioproducts, West Sacramento, CA, USA),
2 mM l-glutamine (Gibco, Grand Island, NY, USA), 1× non-
essential amino acids (Gibco, Grand Island, NY, USA), 10 mM
HEPES (Gibco, Grand Island, NY, USA), 2.5 mM Sodium pyruvate
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(Lonza, Walkersville, MD, USA), 100 U/ml Penicillin, 100µg/ml
streptomycin (Sigma-Aldrich, St. Louis,MO,USA), 50µg/ml Gen-
tamicin (Gibco, Grand Island, NY, USA)] and stained for flow
cytometry in 12 mm× 17 mm tubes using methods previously
described (69, 71). Briefly, 1× 106 cells were plated and washed
with flow cytometry staining (FC) buffer (4% FCS, 1× PBS) and
0.02 Sodium Azide). Cells were blocked with human IgG (50µl
of a 600µg/ml solution in FC buffer) (Sigma, St Louis, MO,
USA) and following one wash, stained with antibody cocktails pre-
pared in FC buffer. Antibodies used included: IgD-FITC (Clone
IA6-2,BD), CD38-PE (Clone HB7, BD), CD19-ECD (Clone J3-
119; BC), CXCR3-PE-Cy5 (Clone 1c6/CXCR3, BD), CD20-PE-
Cy7 (Clone L27, BD), CD3-Pacific Blue (Clone UCHT1, BD),
CD14 (Clone TuK4, Caltag), integrinα4β7-Alexa 647 (Clone ACT-
1); CD27-APC-Alexa700 (clone: 1A4CD27; BC), CD62L-APC-
Alexa750 (Clone Dreg-56, Caltag), IgG-Biotin (Clone 12G5, BD),
and IgA-Biotin (Clone G20-359, BD). Staining was performed at
4°C in the dark for 30 min. After washing the cells (2× with FC
buffer), Pacific Orange–Streptavidin was added to each sample
(Invitrogen, Carlsbad, CA, USA) (30 min) followed by two washes.
Stained cells were fixed with 1% PFA in PBS and samples collected
in a custom LSRII flow cytometer analyzer (BD, USA). Samples
were analyzed using a FlowJo software package (Tree Star, USA).
STATISTICAL METHODS
For each randomized group, we calculated the proportion of sub-
jects manifesting solicited clinical reactions and specific immuno-
logic responses to vaccination. The geometric means and median
values were calculated for serum antibody levels and ASC. Pre-
vaccination and post-vaccination antibody titers and ASC counts
at different time points were evaluated by one-way ANOVA with
Dunnett’s post-test using day 0 as comparator. Post-vaccination
ASC counts (D7) and serum antibody titers (D14) in each reac-
togenicity group as well as homing of sorted ASC were compared
using the Mann–Whitney test. The percentages of CPB cells and
CD27− PB cells, pre-vaccination and post-vaccination were com-
pared using the Mann–Whitney test. Spearman’s correlation coef-
ficient was used to assess relationships between ASC (day 7) and
the percentage of CPB cells and CD27− PB cells (day 7). The same
correlation test was used to assess the relationship between anti-
body titers and the percentage of CPB or CD27− PB cells (day
7). Comparison of multiple homing markers expressed by CPB
and CD27− PB cells was done by one-way ANOVA with Bon-
ferroni’s post-test. Microsoft Excel, GraphPad Prism, NCSS, and
STATA were used for statistical analysis. All hypotheses were eval-
uated using two-sided tests. Two-sided p-values <0.05, without




Two cohorts were inoculated. Cohort 1 was composed of seven
vaccinees (estimated inoculum 2.5× 109 cfu) and one placebo
recipient. Cohort 2 was composed of 10 vaccinees (estimated
inoculum 3.3× 109 cfu) and two placebo recipients. Cohorts were
immunized 2 days apart. The occurrence of fever (17.6%), diar-
rhea (23.5%), and/or vomiting (5.8%) (Table 2) met criteria for
antibiotic administration. Cohort 1 and 2 received antibiotics 4
and 1–2 days after immunization, respectively. No further vacci-
nations were administered. Even though the study was terminated
early and no more cohorts vaccinated, safety follow-ups, stool
cultures for fecal shedding of vaccine (unpublished data), and
immunologic assays on days 7 and 28 were collected in the two
cohorts that received the vaccine.
ANTI-SHIGELLA HUMORAL IMMUNE RESPONSES INDUCED BY CVD
1208S
CVD 1208S induced significant rises in anti-LPS IgA antibody
titers compared to baseline at 7 and 14 days post-immunization,
which began to diminish by day 28 (Figure 1; Table 2). By day 14
(peak day of anti-LPS IgA antibody production), 70.6% (12 of 17)
of vaccinated volunteers had seroconverted (less than or equal to
fourfold-increase (FI) over day 0) (Figure 1A). In contrast, placebo
recipients did not develop anti-LPS IgA antibodies at any time
point (Figure 1D). LPS-specific PB IgA ASC were detected 7 days
post-immunization in all vaccinees (Figure 1B) but in none of the
placebo recipients (data not shown). Moreover, LPS-specific IgA
ASC was positively correlated with anti-LPS IgA antibody titers (at
peak – D14) (Spearman’s correlation) (Figure 1C).
CVD 1208S also induced elevated anti-LPS IgG antibody titers;
however, these were less robust than the IgA responses (Figure 1;
Table 2). By day 14 (IgG peak), 41% of the vaccinated volunteers
(7 of 17) had seroconverted (Figure 1E). IgG LPS-ASC were also
identified on day 7 (Figure 1F) and the presence of these cells
also correlated anti-LPS IgG (FI) at day 14 (Spearman’s correla-
tion) (Figure 1G). Placebo recipients did not develop anti-LPS
IgG responses at any time point (Figure 1H).
CVD 1208S also evoked antibodies (IgA and IgG) against the
protein antigen IpaB; 35.3% (6 of 17) of the vaccinated volunteers
seroconverted to IgA and 52.9% (9 of 17) to IgG by day 14 post-
immunization (Figures 2A,E, respectively). Anti-IgA IpaB-ASC
were also increased in peripheral blood (day 7) (Figure 2B) and
the frequency of these cells correlated with the anti-IpaB antibody
titers (day 7 FI over day 0) (Spearman’s correlation) (Figure 2C).
On the other hand, anti-IgG IpaB-ASC were identified in only two
volunteers (day 7) (Figure 2F) and no correlation with antibody
titers was identified (Figure 2G).
The immune responses of volunteers that showed reactogenic-
ity were compared to the vaccinees who remained asymptomatic.
Although vaccinees without symptoms showed somewhat higher
IgG and IgA seroconversions and ASC responses than vaccinees
who exhibited reactogenicity, these differences did not reach a
point of statistical significance (data not shown). Furthermore,
to determine if the length of exposure to the vaccine had effects
on the strength of the immune responses elicited, we compared
cohorts 1 and 2. No significant differences in antibody titer or
ASCs to LPS or IpaB were identified between these cohorts (data
not shown).
ASC EXPRESSING INTESTINAL HOMING MARKERS PRODUCE
SHIGELLA-SPECIFIC ANTIBODIES
To study the homing potential and antigen-specific production
of PB cells (ASC), freshly isolated PBMC from day 7 post-
immunization were fluorescently sorted into four populations of B

























































Toapanta et al. Shigella induces gut-homing plasmablasts
FIGURE 1 | Anti-LPS IgA and IgG immune responses to CVD 1208S.
(A,E) Anti-LPS IgA and IgG serum levels before and at days 7, 14, and 28 after
immunization. Seroconversion was defined as a≥4-fold-increase (dotted line)
in antigen-specific antibody titers compared to day 0. (B,F) ASC anti-LPS IgA
and IgG (ELISpot) before and at days 7 and 28 after immunization.
(C,G) Spearman’s correlation between anti-LPS IgA and IgG antibody titers
(fold-increase at day 14) and ASC (day 7). (D,H) Sera anti-LPS IgA and IgG in
placebo volunteers (n=3). In all plots each symbol indicates an individual
volunteer. Dotted lines indicate seroconversion (fourfold-increase over day 0).
Horizontal bars represent the median in all graphs. Asterisks show statistical
significance when compared to day 0 (*p<0.05; **p<0.005;
***p<0.0005).
cells (CD19+) based on the expression of CD27 and homing mark-
ers (integrinα4β7 or CD62L) (Figure 3A). B cells expressing CD27
and integrin α4β7, but not CD62L have the potential to migrate to
the gut mucosa (M). On the other hand, B cells expressing CD27
and CD62L, but not integrin α4β7 migrate to peripheral lym-
phoid organs (P). Finally, B cells expressing CD27, integrin α4β7,
and CD62L have dual migration potential (M/P). Sorted cells were
then assayed for antibody production to specific Shigella-LPS by
ELISpot. The results indicated that cells expressing integrin α4β7
alone (M) or in combination with CD62L (M/P), but not in those
expressing only CD62L (P), were responsible for production of
specific anti-Shigella-LPS IgA and IgG antibodies (Figures 3B–E).
Control groups included naïve B cells (CD19+ CD27−) that did
not produce antigen-specific antibodies (data not shown). Similar
results, albeit of lower intensity, were observed in the prior Phase 1
clinical trial (CVD 24000) (65) in which subjects were immunized
with CVD 1208S grown in Hy-Soy agar (Figures 3F–I).
INCREASE IN THE FREQUENCY OF CONVENTIONAL PLASMABLASTS
AND CD27-PLASMABLASTS FOLLOWING ORAL IMMUNIZATION WITH
CVD 1208S
Multichromatic flow cytometry was used to further analyze the
expression of homing markers in PB cells. This technique allowed
simultaneous evaluation of multiple homing markers, including
integrin α4β7, CD62L, CXCR3, and CXCR4 as well as the activa-
tion marker HLA-DR. CPB cells were identified in freshly isolated
PBMC and defined as CD19dim CD20− CD27+(high) CD38+(high)
(Figure 4). These cells did not express surface Igs (IgD, IgG, and
IgA, data not shown). Interestingly, another population of PB
cells that lacked expression, CD27 (henceforth named CD27− PB)
was also observed. Similar to CPB cells, CD27− PB cells did not
express surface Igs (data not shown). Moreover, these cells were
less frequent than CPB at day 0 (average fourfold lower frequency)
(Figure 4 and data not shown). CPB and CD27− PB cells showed
a basal expression of HLA-DR as well as homing markers CD62L
and integrin α4β7. Low basal expression of the homing markers
CXCR3 and CXCR4 was also observed in both CPB and CD27−
PB cells (Figure 4). On day 7 post-vaccination, a statistically sig-
nificant increase in the percentage of CPB and CD27− PB cells
(as percentage% of CD19+CD3− cells), compared to day 0, was
identified (Figure 5). However, CPB showed a higher increase than
CD27− PB cells (4-fold vs. 2.5-fold, respectively) (Figures 5A–C).
By day 28, the percentage of CPB and CD27− PB cells had returned
to pre-vaccination levels (Figures 5B,C). CPB and CD27− PB cells
from placebo immunized volunteers did not show changes at any
of the time points examined (data not shown).
Plasmablast cells have been reported to correlate with antibody
production (Figures 2–4) (53, 72). However, because flow cytom-
etry does not allow evaluation of antigen-specificity of these cells,
we evaluated the relationship between the presence of PB cells
and antigen-specific ASC by Spearman’s correlations. As expected,
anti-LPS-ASC (IgA and IgG) correlated significantly with CPB
cells (day 7, P < 0.05). Interestingly, the same correlation was
found with CD27− PBs (Table 3).
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Table 2 | Reactogenicity and humoral responses in vaccinated volunteers and placebo controls.
ID Reactogenicity Humoral immure responses
Fever Vomiting Loose Stools Anti-LPS IgA Anti-LPS IgG Anti-IpaB IgA Anti-IpaB IgG
°C #Episodesb #Episodes ASCc Ab titer FId ASC Ab titer FI ASC Ab titer FI ASC Ab titer FI













1 2 323 7.5 6 2.5 0 1.1 0 10.9
3f 38.8 (1) 5/4 (1/2) 98 4.7 41 1.5 0 155.3 0 17.9
4 4 (2) 1114 103.6 1052 15.1 107 14.2 0 22.7
6 556 39.9 12 8.1 0 1.5 0 11.3
7 3 (1) 592 13.0 139 6.4 0 1.3 0 2.0
8 208 13.5 44 3.2 28 2.4 11 2.3
9 566 22.9 77 5.0 4 1.5 0 1.6







11 88 4.1 37 2.1 26 2.0 13 1.1
14 76 2.1 55 1.7 40 4.2 0 6.7
15 298 2.6 109 5.9 0 1.0 0 0.5
16 51 2.0 2 0.8 56 2.8 0 2.2
17 38.2 (1) 130 4.3 32 2.2 248 46.2 0 138.7
18 236 113.3 34 4.1 0 1.0 0 6.5
19 39.3 (1) >5/5 (1/2) 8/>5 (1/2) 98 2.5 54 1.9 400 41.0 0 198.3





o 5 0 1.3 0 1.1 0 1.2 0 1.1
12 0 1.1 0 0.9 0 1.0 0 1.0
13 0 0.9 0 0.9 0 1.5 0 0.5
aDay(s) on which the clinical sign was recorded.
bEpisodes in 24 h.
cASC per 1×106 cells on day 7 post-immunization. Bolded results indicate >8 spots per 1×106 cells.
dAntibody titer fold-increase (FI) at peak post-immunization. Bolded results indicate >fourfold-increase (seroconversion).
fThis volunteers reported fever of 39°C and six loose stools on the phone, but recorded 38.8°C and five stools in the diary.
CVD 1208S INCREASED EXPRESSION OF INTEGRIN α4β7, CXCR3, AND
HLA-DR IN CPB AND CD27-PB CELLS
Expression of CD62L and integrin α4β7 was evaluated in CPB
and CD27− PB cells (Figures 6 and 7, respectively). Using these
markers, four different populations (P, M/P, M, and DN), each
one with a different homing (migration) potential, were identified
(Figure 6). On day 7 post-immunization, CPB and CD27− PB
from vaccinated volunteers showed a significant increase in the
expression of integrin α4β7 (M) and down-regulation of CD62L
(P) (Figures 6A,B). The percentage of cells with dual migration
potential (M/P) increased only in CPB (Figures 6B and 7B). By
day 28, expression of integrin α4β7 and CD62L had returned to
their basal levels (Figures 6A,B and 7A,B). In contrast, these mark-
ers remained unaltered in placebo recipients at every time point
assayed (Figures 6A,C and 7C). Expression of the chemokine
receptor CXCR3 and HLA-DR were also significantly elevated
in CPB and CD27− PB cells on day 7 post-immunization and
returned to pre-vaccination levels by day 28 (Figure 8). Expres-
sion of CXCR4 remained unchanged throughout the study (data
not shown). Additionally, expression of integrin α4β7, CD62L,
and CXCR3 alone or in combinations was assayed in CPB and
CD27− PB cells. This analysis was performed only on day 7
because this is the time point at which these markers showed sig-
nificant changes. Expression of CXCR4 was excluded from the
analysis since this marker did not show significant changes at
the time points measured. The results indicated that CPB cells
preferentially up-regulated integrin α4β7 alone and expression of
this marker alone was statistically significant (p< 0.0005) when
compared to all the other possible combinations, except for cells
co-expressing integrin α4β7/CXCR3 (Figure 9A). CD27− PB cells
also preferentially up-regulated integrinα4β7 alone and this group
was statistically significant compared to all other groups (except
for α4β7− CD62L− CXCR3−) (Figure 9B). However, this group
(integrin α4β7 alone) did not represent the most abundant cells
since CD27− PB that did not express any of the assayed homing
markers, was the most abundant and statistically significantly dif-
ferent (p< 0.0005) from all other groups (including integrin α4β7
alone).
EFFECT OF REACTOGENICITY AND LENGTH OF EXPOSURE TO CVD 1208S
ON CPB AND CD27− PB CELLS
To determine if reactogenicity was associated with the frequency
of CPB and CD27− PB cells, we compared the percentage increases
of these cells (day 7 post-immunization) between vaccinees who

























































Toapanta et al. Shigella induces gut-homing plasmablasts
FIGURE 2 | Anti-IpaB immune responses to CVD 1208S. (A,E) Anti-LPS
IgA and IgG serological responses before and at days 7, 14, and 28 after
immunization. (B,F) ASC anti-LPS IgA and IgG (ELISpot) responses,
respectively, before and at days 7 and 28 after immunization.
(C,G) Spearman’s correlation between anti-LPS IgA and IgG antibody titers
(fold-increase at day 14) and ASC (day 7). (D,H) Sera anti-LPS IgA and IgG in
placebo volunteers (n=3). In all plots each symbol indicates an individual
volunteer. Dotted lines indicate seroconversion (fourfold-increase over day 0).
Horizontal bars represent the median in all graphs. Asterisks show statistical
significance when compared to day 0 (*p<0.05).
developed reactogenicity and those who did not. The results indi-
cated that there were no statistically significant differences between
these two groups (data not shown). Similar comparisons were per-
formed for the other markers evaluated (α4β7, CXCR3, and HLA-
DR) but no significant differences were identified. Finally, these
markers in PB and CD27− PB cells were also compared between
volunteers of the first and second cohort and no statistically
significant differences were identified (data not shown).
DISCUSSION
Two inpatient Phase 1 trials in which 14 healthy adults received
ca. 109 cfu of the live, attenuated freshly harvested S. flexneri 2a
vaccine candidate CVD 1208 (grown in animal-containing media)
(66) or CVD 1208S (grown in animal-free media) (65) suggested
that deletions in guaBA, sen, and set resulted in a strain that
was well-tolerated while retaining the ability to evoke an immune
response. In the current study in which subjects received a freshly
harvested vaccine formulation grown in an animal product-free
medium not previously used in our clinical trials, a proportion
of subjects experienced reactogenicity that was attributed the new
growth medium. In fact, the reactogenicity reported in this man-
uscript was unexpected, since neither the previous two trials cited
above (65, 66) nor a follow up clinical trial with CVD 1208S
prepared under GMP (manuscript in preparation) resulted in
any adverse effects. Even though the present trial was halted, it
provided an unprecendented opportunity to study in depth the
induction of humoral immune responses to Shigella after a brief
(1–4 days) exposure to an attenuated vaccine before antibiotic
treatment was initiated. Furthermore, this study allowed us to
evaluate the homing patterns of PB (CPB and CD27− PB cells)
elicited by immunization.
Despite the short exposure time frame (4 days for cohort one
and 1–2 days for cohort 2), CVD 1208S elicited both anti-LPS and
anti-IpaB antibodies (IgA and IgG) with the LPS responses being
more prominent (Figures 1 and 2; Table 2) (65). The cells respon-
sible for the initial production of antigen-specific antibodies are
PB (60) and consistent with this phenomenon, anti-LPS-ASC IgA
and IgG (at day 7) correlated with anti-LPS IgA and IgG anti-
body titers (FI at day 14), respectively (Figures 1C,G). Similarly,
anti-IpaB IgA ASC correlated with antibody titers (IgA at day 7)
(Figure 2C). Anti-IpaB IgG ASC were detected only in a few volun-
teers, although significantly higher antibody titers were detected
by ELISA. This suggests that there are still limitations in the assays
used to detect PB, particularly for poorly immunogenic anti-
gens (e.g., IpaB), and that a complete assessment of the immune
responses can only be achieved by combining the results from mul-
tiple assays. In the present studies, anti-LPS responses appeared to
be transitory since IgA and IgG titers increased on days 7 and 14,
but began to decrease by day 28. On the other hand, anti-IpaB
IgA and IgG antibody titers remained elevated up to day 28 (the
last time evaluated). These results confirm and extend previously
published data (65, 66).
The seroconversion rate induced by CVD 1208S in this trial
(~70% for anti-LPS IgA) is similar to the one we previously
reported for CVD 1208 (71%) (66) and higher than in a previous
CVD 1208S trial (14%) (65). Therefore, these results indicate that
in the present studies CVD 1208S appeared to be similar, or more,
immunogenic than previous trials, suggesting that the enhanced
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FIGURE 3 | Homing potential of sorted B cells. (A) Freshly isolated
PBMC (day 7) were stained with CD19, CD27, CD62L, and integrin α4β7
markers and then immediately sorted using a MoFlow cytometer
(Beckman-Coulter) as depicted in the graph (for details see the Materials
and Methods section). An aliquot of the sorted populations was run in the
cytometer to confirm purity of the samples (>90%). As a negative control,
naïve B cells (CD19+ CD27−), which had been demonstrated in previous
experiments not to produce antibodies, were also sorted. P indicates cells
expression of CD62L (homing to peripheral lymphoid tissues). M indicates
expression of integrin α4β7 (homing to the gut). M/P indicates
co-expression of integrin α4β7 and CD62L. DN cells, which did not express
either integrin α4β7 or CD62L, were not sorted. Sorted cells were assayed
for antibody production by ELISpot in plates coated with LPS or IpaB.
Anti-LPS IgA (B) and IgG (C) ASC were identified in cells homing to gut
mucosal tissues (M) and those with dual potential (M/P), but not in those
expressing only CD62L (P). Similar results were shown in anti-IpaB IgA (D)
and IgG (E). (F–I) Results from similar sorting experiments using PBMC
from a previous CVD 1208S Phase 1 vaccine trial. The numbers of
volunteers (n) that responded to the stimulants and were used to generate
each of the graphs are indicated.
immunogenicity could be attributed to reactogenicity; however,
this does not appear to be the case since no differences in the
strength of the immune responses were observed between the vol-
unteers with and without reactogenicity. Additionally, CVD 1208S
appears to be at least as immunogenic as other live-attenuated
oral vaccines, such as Ty21a, the licensed oral attenuated typhoid
vaccine, which typically exhibits a seroconversion rate of 40–60%
(73–75).
Several reports have shown that PB cells appear in peripheral
blood on day 7 post-infection or vaccination (45, 53, 60, 72).
Consistent with these observations, we identified LPS- and IpaB-
specific (IgA and IgG) ASC (ELISpot) on day 7 post-vaccination.
Furthermore, PB cells are believed to ultimately migrate and home
in the gut mucosa, the environment where they will produce
antibodies. It is widely accepted that expression of integrin α4β7
promotes migration of cells to intestinal sites, while expression of
CD62L promotes migration to peripheral lymphoid tissues, par-
ticularly lymph nodes. Consistent with this hypothesis, we found
that sorted ASC that expressed either integrin α4β7 alone or in
combination with CD62L, but not the ones that expressed only
CD62L were responsible for antigen-specific antibody production,
providing the first direct evidence of the relevance of gut-homing
in subjects orally immunized with attenuated Shigella vaccines
(Figures 3B–E). Of importance, similar results, albeit at lower
intensity, were obtained in a previous Phase I clinical trial (CVD
24000) (Figures 3F–I).
We used multichromatic flow cytometry to characterize in
depth the expression of homing markers by PB cells. Homing
markers were assayed at various time points (days 0, 7, and 28)
to determine differences in expression as the humoral immune
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FIGURE 4 | Gating strategy for “conventional plasmablast” (CPB) and
“CD27− plasmablast” (CD27− PB) cells. Example of gating strategy used
(day 0) in a representative volunteer. CPB cells were defined as CD19dim
CD20− CD27+(high) CD38+(high) (IgD− IgG− IgA−). CD27− PB cells were
defined as CD19dim CD20− CD27− CD38+(high) (IgD− IgG− IgA−). Expression
of the homing molecules integrin α4β7 and CD62L was determined in both
subpopulations. P indicates cells expressing only CD62L, which home
preferentially to peripheral lymphoid tissues. M indicates cells expressing
only integrin α4β7, homing preferentially to the gut mucosa. M/P indicates
cells co-expressing integrin α4β7 and CD62L (dual homing potential). DN
indicates cells expressing neither CD62L nor integrin α4β7. Expression of
other homing molecules including CXCR3 and CXCR4 as well as the
activation marker HLA-DR were also evaluated in CD27-PB and CPB
subsets.
FIGURE 5 | Percentage of CPB and CD27− PB cells following oral
immunization. (A) Example of population gating (CPB and CD27− PB cells)
at different time points (days 0, 7, and 28) in a representative vaccinated
volunteer. (B,C) Show a compilation of the percentage of CPB and CD27−
PB (as percentage of CD19+ CD3−), respectively, from all vaccinees. Bars
indicate arithmetic mean (±SEM). Asterisks show statistical significance
when compared to day 0 (*p<0.05; **p<0.005).
responses were developing. PB cell were defined as CD19dim
CD20− CD27+(high) CD38+(high) CD3− and referred to as CPB,
due to the identification of a second group of PB cells that
Table 3 | Correlation between anti-Shigella-LPS-ASC responses and
changes in the percentages of CPB or CD27- PB cells.
Correlated groupsa All volunteers
Pd re CIf
α-LPS IgA ASC (D7) and % CPBb (D7) 0.0292 0.857 0.15–0.98
α-LPS IgG ASC (D7) and % CPB (D7) 0.0005 0.754 0.43–0.91
α-LPS IgA ASC (D7) and % CD27-PBc (D7) 0.0312 0.5231 0.05–0.80
α-LPS IgG ASC (D7) and % CD27-PB (D7) 0.0103 0.604 0.17–0.84
aSpearman’s correlation coefficient was used.
b% CPB=% of conventional plasmablast cells from the CD19+ gate.




lacked the expression of CD27, which were referred as CD27−
PB (Figure 4). CPB cells not only increased in frequency by
day 7 post-immunization (Figures 5A,B), but also exhibited
increased expression of integrin α4β7, while the expression of
CD62L declined, further supporting the hypothesis that these
cells ultimately migrate to the intestinal mucosa (Figures 6A,C).
Another homing marker that was increased in CPB cells on
day 7 was CXCR3, which promotes migration to inflamed tis-
sues (Figures 8A,B) (50, 64). Thus, it is reasonable to speculate
that following vaccination with an attenuated strain of Shigella,
a mild inflammation of the gut mucosa would further promote
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FIGURE 6 | Expression of homing molecules by CPB cells. CPB cells
[CD19dim CD20−CD27+(high) CD38+(high)] were gated as described in Figure 5
CPB cells were assayed for the expression of integrin α4β7 and CD62L to
evaluate their homing potential. (A) Representative example of the changes
in integrin α4β7 and CD62L expression in CPB cells at different time points
(days 0, 7, and 28) in vaccine (top 3 panels) and placebo (bottom three
panels). (B,C) Compiled data of the expression of homing receptors in CPB
cells in vaccine and placebo recipients, respectively. Bars indicate
arithmetic mean (±SEM). White, black and gray bars indicate days 0, 7, and
28, respectively. Horizontal lines indicate groups compared and asterisks
indicate statistical significance (***p<0.0005). In the inset: P indicates
cells expression of CD62L only. M indicates expression of integrin α4β7
only. M/P indicates co-expression of integrin α4β7 and CD62L.
CPB cells to home in those sites. Not surprisingly, CPB cells also
showed increased levels of activation on day 7 post-vaccination
as evidenced by the upregulation of HLA-DR (Figures 8C,D), a
phenomenon also associated with differentiation into PC (54).
Interestingly, no changes were noted in the expression of CXCR4
(data not shown), a chemokine that favors homing in the bone
marrow. This observation suggests that few, if any, of the CPB
induced by a mucosal pathogen (or vaccine) will home in the
bone marrow. The preferred homing site of these cells remains
to be identified. The lack of expression of CXCR4 and increased
expression of integrin α4β7 also suggest that most CPB produce
IgA as proposed by recent studies (54). Spearman’s correlation
analysis suggested that the CPB cells identified by flow cytometry
were indeed those detected by ELISpot assays (ASC) (Table 3).
Finally, analysis of co-expression of homing molecules indicated
that the vast majority of these cells express either integrin α4β7
alone or in combination with other homing marker(s) (Figure 9),
further confirming that these cells are likely to migrate to the
intestinal mucosa and inflamed tissues (combined CPB express-
ing integrin α4β7 alone or with other markers was found to be
~80). Therefore, it appears that only ~20% of CPB elicited after
FIGURE 7 | Expression of homing molecules by CD27− PB cells. CD27−
PB cells [CD19dim CD20− D27− CD38+(high)] were gated as indicated in
Figure 4. Similar to CPB cells, CD27− PB cells were evaluated for the
expression of CD62L and integrin α4β7 to determine their homing potential
(A–C). (A) Representative example of the increase in integrin α4β7 and
reduction of CD62L at day 7. (B,C) Compiled data of all vaccinated (B) and
placebo (C) volunteers at each time point evaluated. White, black and gray
bars indicate days 0, 7, and 28, respectively. Bars in plots indicate arithmetic
mean (±SEM). Horizontal lines indicate groups compared and asterisk
indicate statistical significance (*p<0.05; ***p<0.0005).
mucosal immunization migrate to tissues other than the intestinal
mucosa.
Interestingly, we identified a population of PB that lacked CD27
expression (CD27− PB; CD19dim CD20− CD27− CD38+(high);
Figure 4). These cells are likely to represent the recently described
pre-plasmablast population (76, 77). However, to our knowledge,
this is the first report describing that these cells are elicited by
oral immunizations in humans. CD27− PB cells were less fre-
quent than CPB (Figure 5C) and showed a somewhat similar
pattern of expression of homing and activation markers than
CPB (Figures 7–9). Despite the fact that integrin α4β7 was also
an important homing marker (alone or combined ~30–35%) in
CD27− PB cells, in contrast to CPB, the largest percentage of
CD27− PB expressed none of the homing markers examined
(~40–50% were quadruple negative for integrin α4β7, CD62L,
CXCR3, and CXCR4) (Figure 9). This suggests that even though
some CD27− PB cells home in the intestinal mucosa, about half of
these cells home in a different lymphoid organ (likely not the bone
marrow), which at present remains unknown. Alternatively, since
CD27− PB are a pre-plasmablast population, the lack of expression
of integrin α4β7 might be a consequence of their immature state

























































Toapanta et al. Shigella induces gut-homing plasmablasts
FIGURE 8 | Expression of CXCR3 and HLA-DR in CPB and CD27− PB cells.
CPB and CD27− PB cells (Figure 5) were also evaluated for the expression of
CXCR3 and HLA-DR. Representative examples of the changes in CXCR3
(A,E) and HLA-DR (C,G) expression at the evaluated time points (Days 0, 7,
and 28) are shown. Compiled data on the expression of CXCR3 (B,F) and
HLA-DR (D,H) in CPB and CD27-PB are shown. Bars indicate arithmetic mean
(±SEM). Asterisks indicate statistical significance when compared to day 0
(*p<0.05; **p<0.005; ***p<0.0005).
and when these cells differentiate into CPB, increased expression
of integrin α4β7 facilitates migration to the gut.
The severity of the disease induced by natural Shigella infections
could have an impact on the strength of the immune responses
elicited; however, it is unknown whether more severe disease
(or vaccine reactogenicity) is associated with either enhanced or
reduced immunogenicity. This is particularly important in vaccine
development, since the goal is to develop immunogenic vaccines
that do not produce reactogenicity; however, this balance has been
difficult to achieve for Shigella. Since some vaccinated volunteers
exhibited side effects, we investigated whether there was an asso-
ciation between reactogenicity and the strength and quality of
the humoral immune responses elicited. Interestingly, no statis-
tically significant differences were observed among the subjects
who developed symptomatology and those who remained asymp-
tomatic for any of the parameters evaluated (e.g., antibody titers,
ASC frequencies, homing potential of ASC, degrees of activation),
although the sample sizes were small. Another interesting obser-
vation derived from these studies relates to the early antibiotic
treatment, which was initiated 1–4 days after immunization in
all volunteers. Based on the strong humoral immune responses
observed, it is reasonable to hypothesize that a relatively short
period of exposure to an attenuated Shigella vaccine (~1–4 days)
is sufficient to elicit strong immunity. A recent report in the S.
typhimurium mouse model suggested that oral treatment with
ciprofloxacin resulted in impaired development of the adaptive
immunity (78). However, this does not appear to be the case in the
current study since oral antibiotic treatment with ciprofloxacin
(500 mg BID for 5 days) did not impair the development of the
strong humoral immune responses.
In sum, we have shown the induction of robust antibody and
ASC responses in subjects orally immunized with the attenuated
Shigella vaccine strain CVD 1208S and characterized in detail the
kinetics and homing potential of CPB and CD27− PB elicited
by vaccination. The observations that strong immune responses
were elicited in individuals who did not show reactogenicity and
that a short period of exposure (1–4 days) was sufficient to elicit
appropriate humoral immunity, provides further impetus for the
continuing development of attenuated Shigella strains to be used
as oral vaccines.
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FIGURE 9 | Co-expression of homing molecules in CPB and CD27− PB
cells. The expression of integrin α4β7, CD62L, and CXCR3 alone or in
combinations (Boolean gates – FlowJo) were assayed in samples from day
7 in CPB and CD27− PB gated cells [(A,B), respectively]. The graph displays
percentages of cells expressing each combination evaluated. Each symbol
indicates an individual volunteer and in each group the bars indicate the
highest and lowest percentages. Horizontal lines indicate the median. The
groups were evaluated by one-way ANOVA, followed by Dunnet’s post-test
using expression of integrin α4β7 alone as the control group.
(A) ***p<0.0005 integrin α4β7 alone versus all other groups except for
integrin α4β7+CXCR3+. NS; not significant. (B) ###p<0.0005 integrin α4β7
alone versus all other groups, except integrin α4β7− CD62L− CXCR3−,
***p< 0.0005 integrin α4β7− CD62L− CXCR3− versus all other groups
except the integrin α4β7+ alone.
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